Table 3.
Univariate Analysis of Risk Factors for Acquisition of ESBL-EK
| Group; No. (%)* | |||
|---|---|---|---|
|
| |||
| Risk Factor | Cases (ESBL-EK) (n = 40) | Controls (non-ESBL-EK) (n = 40) | p Value |
| Prior antibiotic use (previous 3 months)* | 19 (48) | 5 (12) | 0.001‡ |
| ß-Lactams† | 9 (22) | 4 (10) | 0.23‡ |
| Fluoroquinolones | 11 (28) | 2 (5) | 0.013‡ |
| Prior travel (previous 3 months) | 5 (12) | 0 (0) | 0.055§ |
| Prior hospital admission (previous 3 months) | 17 (42) | 8 (20) | 0.03‡ |
| Hospital stay > 14 days | 7 (18) | 7 (18) | > 0.99‡ |
| Residence in long-term care facility | 2 (5) | 7 (18) | 0.15§ |
| Current malignancy | 11 (28) | 13 (32) | 0.63‡ |
| Diabetes mellitus | 12 (30) | 12 (30) | > 0.99‡ |
| Mechanical ventilation | 3 (8) | 1 (2) | 0.62§ |
| Charlson score > 2 | 16 (40) | 17 (42) | 0.82‡ |
| Urinary catheterization | 10 (25) | 10 (25) | > 0.99‡ |
| Central line catheterization | 14 (35) | 8 (20) | 0.13‡ |
| Age ≥ 65 years old | 18 (45) | 23 (58) | 0.26‡ |
ESBL-EK = Escherichia coli and Klebsiella species producing extended-spectrum ß-lactamase, non-ESBL-EK = Escherichia coli and Klebsiella species not producing extended-spectrum ß-lactamase.
*
In each group, one patient received both ß-lactam and fluoroquinolone therapy.
†
Excludes carbapenems.
‡
By χ2 test.
§
By Fisher exact test.